Citations (48)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Miao Yan, Wenqun Li, Wen-Bo Li, Qi Huang, Jing Li, Hua-Lin Cai, Hui Gong, Bi-Kui Zhang & Yi-Kun Wang. (2023) Metabolic activation of tyrosine kinase inhibitors: recent advance and further clinical practice. Drug Metabolism Reviews 55:1-2, pages 94-106.
Read now
Read now
Haochen Jiang, Ying Jin, Hao Yan, Zhifei Xu, Bo Yang, Qiaojun He & Peihua Luo. (2021) Hepatotoxicity of FDA-approved small molecule kinase inhibitors. Expert Opinion on Drug Safety 20:3, pages 335-348.
Read now
Read now
Gloria Ravegnini, Giorgia Valori, Qianqian Zhang, Riccardo Ricci, Patrizia Hrelia & Sabrina Angelini. (2020) Pharmacogenetics in the treatment of gastrointestinal stromal tumors – an updated review. Expert Opinion on Drug Metabolism & Toxicology 16:9, pages 797-808.
Read now
Read now
S. Cyrus Khojasteh, James P. Driscoll, Klarissa D. Jackson, Grover P. Miller, Kaushik Mitra, Ivonne M. C. M Rietjens & Donglu Zhang. (2020) Novel advances in biotransformation and bioactivation research—2019 year in review. Drug Metabolism Reviews 52:3, pages 333-365.
Read now
Read now
Jonathan G. Stine & James H. Lewis. (2016) Current and future directions in the treatment and prevention of drug-induced liver injury: a systematic review. Expert Review of Gastroenterology & Hepatology 10:4, pages 517-536.
Read now
Read now
Articles from other publishers (43)
Khalid Alhazzani, Salah Q Alrewily, Khaldoon Aljerian, Khaled Alhosaini, Mohammad M. Algahtani, Mohammed Fhad Almutery, Abdullah S Alhamed, Ahmed Nadeem, Moureq R. Alotaibi & Ahmed Z. Alanazi. (2023) Hydroxychloroquine ameliorates dasatinib-induced liver injury via decrease in hepatic lymphocytes infiltration. Human & Experimental Toxicology 42.
Crossref
Crossref
Yee Hui Yeo, Walid Ayoub, Ju Dong Yang, Alexander Kuo & Hirsh D. Trivedi. (2023) Beyond the Checkpoint: Severe Axitinib-induced Liver Injury. ACG Case Reports Journal 10:11, pages e01177.
Crossref
Crossref
Mitchell R. McGill, Yihong Kaufmann, Francesca V. LoBianco, Mary A. Schleiff, Nukhet Aykin-Burns & Grover P. Miller. (2023) The Role of Cytochrome P450 3A4-Mediated Metabolism in Sorafenib and Lapatinib Hepatotoxicity. Livers 3:2, pages 310-321.
Crossref
Crossref
Arsh Haj Mohamad Ebrahim Ketabforoush, Rojin Chegini, Shirin Barati, Fatemeh Tahmasebi, Bardia Moghisseh, Mohammad Taghi Joghataei, Faezeh Faghihi & Fereshteh Azedi. (2023) Masitinib: The promising actor in the next season of the Amyotrophic Lateral Sclerosis treatment series. Biomedicine & Pharmacotherapy 160, pages 114378.
Crossref
Crossref
Dehua Liao, Lun Yu, Shanshan Chen, Ni Liu, Jingyi Tang & Nong Yang. (2023) The safety profile of EGFR/ALK-TKIs administered immediately before or after ICIs in advanced NSCLC. International Immunopharmacology 116, pages 109787.
Crossref
Crossref
Shengde Wu, George Daston, Jane Rose, Karen Blackburn, Joan Fisher, Allison Reis, Bastian Selman & Jorge Naciff. (2023) Identifying chemicals based on receptor binding/bioactivation/mechanistic explanation associated with potential to elicit hepatotoxicity and to support structure activity relationship-based read-across. Current Research in Toxicology 5, pages 100108.
Crossref
Crossref
Hana Studentova, Jindriska Volakova, Martina Spisarova, Anezka Zemankova, Kvetoslava Aiglova, Tomas Szotkowski & Bohuslav Melichar. (2022) Severe tyrosine-kinase inhibitor induced liver injury in metastatic renal cell carcinoma patients: two case reports assessed for causality using the updated RUCAM and review of the literature. BMC Gastroenterology 22:1.
Crossref
Crossref
Jeffrey H. Lipton, Tim H. Brümmendorf, Carlo Gambacorti-Passerini, Valentin Garcia-Gutiérrez, Michael W. Deininger & Jorge E. Cortes. (2022) Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option. Blood Reviews 56, pages 100968.
Crossref
Crossref
Morgane Clément, Jean-Paul Cervoni, Florian Renosi, Thierry Thévenot, Sophie Felix, Alexandre Doussot, Bruno Heyd, Éric Deconinck & Vincent Di Martino. (2022) Acute fulminant hepatitis related to the use of dasatinib: First case report. Clinics and Research in Hepatology and Gastroenterology 46:8, pages 102004.
Crossref
Crossref
Bethany D. Latham, D. Spencer Oskin, Rachel D. Crouch, Matthew J. Vergne & Klarissa D. Jackson. (2022) Cytochromes P450 2C8 and 3A Catalyze the Metabolic Activation of the Tyrosine Kinase Inhibitor Masitinib. Chemical Research in Toxicology 35:9, pages 1467-1481.
Crossref
Crossref
Qi Zhao, Zhanxuan E. Wu, Bin Li & Fei Li. (2022) Recent advances in metabolism and toxicity of tyrosine kinase inhibitors. Pharmacology & Therapeutics 237, pages 108256.
Crossref
Crossref
Manuel Ramos-Casals, Alejandra Flores-Chávez, Pilar Brito-Zerón, Olivier Lambotte & Xavier Mariette. (2022) Immune-related adverse events of cancer immunotherapies targeting kinases. Pharmacology & Therapeutics 237, pages 108250.
Crossref
Crossref
Ivana Puliafito, Francesca Esposito, Angela Prestifilippo, Stefania Marchisotta, Dorotea Sciacca, Maria Paola Vitale & Dario Giuffrida. (2022) Target Therapy in Thyroid Cancer: Current Challenge in Clinical Use of Tyrosine Kinase Inhibitors and Management of Side Effects. Frontiers in Endocrinology 13.
Crossref
Crossref
Feng-Ru Huang, Wen-Tong Fang, Zi-Ping Cheng, Ye Shen, Dun-Jian Wang, Yong-Qing Wang & Lu-Ning Sun. (2022) Imatinib-induced hepatotoxicity via oxidative stress and activation of NLRP3 inflammasome: an in vitro and in vivo study. Archives of Toxicology 96:4, pages 1075-1087.
Crossref
Crossref
Lu Xie, Jie Xu, Wei Guo, Zhen Wang, Yang Yao, Jianmin Li, Jianhua Lin, Jianru Xiao, Xiuchun Yu, Weibin Zhang, Zhendong Cai, Yingqi Hua, Jing Chen, Zengwu Shao, Di Wu, Sujia Wu, Zhongqi Tu & Xiaojing Zhang. (2021) Management of Apatinib-Related Adverse Events in Patients With Advanced Osteosarcoma From Four Prospective Trials: Chinese Sarcoma Study Group Experience. Frontiers in Oncology 11.
Crossref
Crossref
Yue Zhuo, Yida Zhang, Meng Li, Haiying Wu, Shilin Gong, Xiaolan Hu, Yu Fu, Xinzi Shen, Baoqing Sun, Jian-Lin Wu & Na Li. (2021) Hepatotoxic evaluation of toosendanin via biomarker quantification and pathway mapping of large-scale chemical proteomics. Food and Chemical Toxicology 153, pages 112257.
Crossref
Crossref
Zhe Wang, Xiaoyu Wang, Zhen Wang, Yuyi Feng, Yaqin Jia, Lili Jiang, Yangliu Xia, Jun Cao & Yong Liu. (2021) Comparison of Hepatotoxicity Associated With New BCR-ABL Tyrosine Kinase Inhibitors vs Imatinib Among Patients With Chronic Myeloid Leukemia. JAMA Network Open 4:7, pages e2120165.
Crossref
Crossref
James H. Lewis, Hans Gelderblom, Michiel Sande, Silvia Stacchiotti, John H. Healey, William D. Tap, Andrew J. Wagner, Antonio Lopez Pousa, Mihaela Druta, Chia-Chi Lin, Hideo A. Baba, Youngsook Choi, Qiang Wang, Dale E. Shuster & Sebastian Bauer. (2021) Pexidartinib Long-Term Hepatic Safety Profile in Patients with Tenosynovial Giant Cell Tumors. The Oncologist 26:5, pages e863-e873.
Crossref
Crossref
Anum Aqsa, Sami Droubi, Shivantha Amarnath, Hassan Al-Moussawi & Jeffrey Abergel. (2021) Sunitinib-Induced Acute Liver Failure. Case Reports in Gastroenterology 15:1, pages 17-21.
Crossref
Crossref
Benjamin C. Creelan, Tammie C. Yeh, Sang-We Kim, Naoyuki Nogami, Dong-Wan Kim, Laura Q. M. Chow, Shintaro Kanda, Rosemary Taylor, Weifeng Tang, Mei Tang, Helen K. Angell, Martine P. Roudier, Marcelo Marotti & Don L. Gibbons. (2020) A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer. British Journal of Cancer 124:2, pages 383-390.
Crossref
Crossref
Camille Houron, Marie Danielou, Olivier Mir, Bernard Fromenty, Gabriel Perlemuter & Cosmin Sebastian Voican. (2021) Multikinase inhibitor-induced liver injury in patients with cancer: A review for clinicians. Critical Reviews in Oncology/Hematology 157, pages 103127.
Crossref
Crossref
Hong Huang, Xue Bai & Lijun Yang. (2020) Intriguing generative metabolism discovery of reactive metabolite nitroso of lapatinib and relevant structural modification. International Journal of Quantum Chemistry 120:12.
Crossref
Crossref
Wimonchat Tangamornsuksan, Chuenjid Kongkaew, C. N. Scholfield, Suphat Subongkot & Manupat Lohitnavy. (2019) HLA-DRB1*07:01 and lapatinib-induced hepatotoxicity: a systematic review and meta-analysis. The Pharmacogenomics Journal 20:1, pages 47-56.
Crossref
Crossref
Jin Young Moon, Ji Min Han, Inyoung Seo & Hye Sun Gwak. (2019) Risk factors associated with the incidence and time to onset of lapatinib-induced hepatotoxicity. Breast Cancer Research and Treatment 178:1, pages 239-244.
Crossref
Crossref
Marie‐Noëlle Paludetto, Florent Puisset, Etienne Chatelut & Cécile Arellano. (2019) Identifying the reactive metabolites of tyrosine kinase inhibitors in a comprehensive approach: Implications for drug‐drug interactions and hepatotoxicity. Medicinal Research Reviews 39:6, pages 2105-2152.
Crossref
Crossref
Alberto Carretero-González, Javier Salamanca Santamaría, Daniel Castellano & Guillermo de Velasco. (2019) Three case reports. Medicine 98:47, pages e18098.
Crossref
Crossref
Artem Lysenko, Alok Sharma, Keith A Boroevich & Tatsuhiko Tsunoda. (2018) An integrative machine learning approach for prediction of toxicity-related drug safety. Life Science Alliance 1:6, pages e201800098.
Crossref
Crossref
Verena Schöning, Stephan Krähenbühl & Jürgen Drewe. (2018) The hepatotoxic potential of protein kinase inhibitors predicted with Random Forest and Artificial Neural Networks. Toxicology Letters 299, pages 145-148.
Crossref
Crossref
Jun Zhang, Lijun Ren, Xi Yang, Matthew White, James Greenhaw, Tashika Harris, Qiangen Wu, Matthew Bryant, Thomas Papoian, William Mattes & Qiang Shi. (2018) Cytotoxicity of 34 FDA approved small-molecule kinase inhibitors in primary rat and human hepatocytes. Toxicology Letters 291, pages 138-148.
Crossref
Crossref
Dominique Béchade, Camille Chakiba, Marie Desjardin, Yves Bécouarn & Marianne Fonck. (2018) Toxicité hépatique des inhibiteurs des tyrosines kinases : mécanismes en cause et conséquences pratiques. Bulletin du Cancer 105:3, pages 290-298.
Crossref
Crossref
Cécile Mingard, Franziska Paech, Jamal Bouitbir & Stephan Krähenbühl. (2018) Mechanisms of toxicity associated with six tyrosine kinase inhibitors in human hepatocyte cell lines. Journal of Applied Toxicology 38:3, pages 418-431.
Crossref
Crossref
Nelia Hernandez. (2017) Hepatotoxicity of New Antitumor Agents. Current Hepatology Reports 16:4, pages 293-297.
Crossref
Crossref
Jun Zhang, Alec Salminen, Xi Yang, Yong Luo, Qiangen Wu, Matthew White, James Greenhaw, Lijun Ren, Matthew Bryant, William Salminen, Thomas Papoian, William Mattes & Qiang Shi. (2016) Effects of 31 FDA approved small-molecule kinase inhibitors on isolated rat liver mitochondria. Archives of Toxicology 91:8, pages 2921-2938.
Crossref
Crossref
Franziska Paech, Jamal Bouitbir & Stephan Krähenbühl. (2017) Hepatocellular Toxicity Associated with Tyrosine Kinase Inhibitors: Mitochondrial Damage and Inhibition of Glycolysis. Frontiers in Pharmacology 8.
Crossref
Crossref
Ivo Vrobel, David Friedecký, Edgar Faber, Lukáš Najdekr, Kateřina Mičová, Radana Karlíková & Tomáš Adam. (2017) Novel sulphur-containing imatinib metabolites found by untargeted LC-HRMS analysis. European Journal of Pharmaceutical Sciences 104, pages 335-343.
Crossref
Crossref
Ralf-Dieter Hofheinz, Siegfried Segaert, María José Safont, Gaston Demonty & Hans Prenen. (2017) Management of adverse events during treatment of gastrointestinal cancers with epidermal growth factor inhibitors. Critical Reviews in Oncology/Hematology 114, pages 102-113.
Crossref
Crossref
Chalermrat Bunchorntavakul & K. Rajender Reddy. (2017) Drug Hepatotoxicity. Clinics in Liver Disease 21:1, pages 115-134.
Crossref
Crossref
Tamara Alempijevic, Simon Zec & Tomica Milosavljevic. (2017) Drug-induced liver injury: Do we know everything?. World Journal of Hepatology 9:10, pages 491.
Crossref
Crossref
Jacqueline L. Olin, J. Andrew Woods & Stuart J. Garner. (2017) Delayed Presentation of Hepatocellular Liver Injury After Nintedanib Administration. American Journal of Therapeutics 24:1, pages e107-e108.
Crossref
Crossref
Kai Qu, Tian Liu, Ting Lin, Xing Zhang, Ruixia Cui, Sinan Liu, Fandi Meng, Jingyao Zhang, Minghui Tai, Yong Wan & Chang Liu. (2016) Tyrosine kinase inhibitors: friends or foe in treatment of hepatic fibrosis?. Oncotarget 7:41, pages 67650-67660.
Crossref
Crossref
Yakov M. Koen, Nadezhda A. Galeva, Imir G. Metushi, Jack Uetrecht & Robert P. Hanzlik. (2016)
Protein Targets of Isoniazid-Reactive Metabolites in Mouse Liver
in Vivo
. Chemical Research in Toxicology 29:6, pages 1064-1072.
Crossref
Crossref
Emanuel Raschi. (2015) Drug- and herb-induced liver injury: Progress, current challenges and emerging signals of post-marketing risk. World Journal of Hepatology 7:13, pages 1761.
Crossref
Crossref
Maria Salvado. (2015) Autoimmune-like hepatitis during masitinib therapy in an amyotrophic lateral sclerosis patient. World Journal of Gastroenterology 21:36, pages 10475.
Crossref
Crossref